文献速递帕金森病与运动障碍神经肌肉病

自身免疫性步态障碍伴适配蛋白3B2-IgG

Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG.
PubMed 文献 · Neurology · 2019-08-01

该研究从616,025份筛查标本中重新评估模拟amphiphysin-IgG的未分类突触抗体,鉴定出10例AP3B2-IgG阳性患者,均表现为亚急性起病的快速进展性步态共济失调,5例接受免疫治疗未改善但随访期未恶化。

要点

  • AP3B2-IgG相关自身免疫罕见,以亚急性步态共济失调为核心表现。
  • 神经表型包括脊髓神经病、感觉神经病、小脑性及脊髓小脑性共济失调。
  • 免疫治疗未显示改善,但随访中未恶化,部分患者可死亡。

核心结论

  • AP3B2自身免疫罕见,伴随感觉性或小脑性共济失调,可能具有治疗潜力。

研究设计与样本

  • 回顾性研究,从616,025份筛查的存档血清和脑脊液标本中重新评估未分类突触抗体。
  • 通过蛋白质印迹和质谱鉴定自身抗原,重组蛋白印迹和细胞结合试验确认特异性。
  • 临床数据回顾性获取,共10例血清阳性患者,其中9例有临床信息。

主要发现

  • 10例患者血清(10份)和脑脊液(6份)标本产生相同IFA染色模式,主要在小脑、脊髓灰质、背根神经节和交感神经节。
  • 质谱分析和重组试验确认抗原为AP3B2。
  • 10例中6例女性,中位症状 onset 年龄42岁(范围24-58)。
  • 9例均有亚急性起病和快速进展性步态共济失调,表型包括脊髓神经病(3例)、周围感觉神经病(2例)、小脑性共济失调(2例)和脊髓小脑性共济失调(2例)。
  • 5例接受免疫治疗,无人改善但随访期(中位36个月,范围3-94)未恶化;2例(均患癌症)死亡。

关键数值与推荐

  • 50份对照血清中1份仅蛋白质印迹阳性(IFA和CBA阴性)。

临床怎么用

  • 对亚急性起病的步态共济失调患者,应考虑检测AP3B2-IgG以识别潜在自身免疫病因。
  • 免疫治疗效果尚不明确,但随访中未恶化,可个体化考虑免疫治疗。

局限性

  • 回顾性研究,样本量小(10例血清阳性,9例临床信息)。
  • 治疗反应数据有限,仅5例接受免疫治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe phenotypes, treatment response, and outcomes of autoimmunity targeting a synaptic vesicle coat protein, the neuronal (B2) form of adaptor protein-3 (AP3). METHODS: Archived serum and CSF specimens (from 616,025 screened) harboring unclassified synaptic antibodies mimicking amphiphysin-immunoglobulin G (IgG) on tissue-based indirect immunofluorescence assay (IFA) were re-evaluated for novel IgG staining patterns. Autoantigens were identified by western blot and mass spectrometry. Recombinant western blot and cell-binding assay (CBA) were used to confirm antigen specificity. Clinical data were obtained retrospectively. RESULTS: Serum (10) and CSF (6) specimens of 10 patients produced identical IFA staining patterns throughout mouse nervous system tissues, most prominently in cerebellum (Purkinje neuronal perikarya, granular layer synapses, and dentate regions), spinal cord gray matter, dorsal root ganglia, and sympathetic ganglia. The antigen revealed by mass spectrometry analysis and confirmed by recombinant assays (western blot and CBA) was AP3B2 in all. Of 10 seropositive patients, 6 were women; median symptom onset age was 42 years (range 24-58). Clinical information was available for 9 patients, all with subacute onset and rapidly progressive gait ataxia. Neurologic manifestations were myeloneuropathy (3), peripheral sensory neuropathy (2), cerebellar ataxia (2), and spinocerebellar ataxia (2). Five patients received immunotherapy; none improved, but they did not worsen over the follow-up period (median 36 months; range 3-94). Two patients (both with cancer) died. One of 50 control sera was positive by western blot only (but not by IFA or CBA). CONCLUSION: AP3B2 (previously named β-neuronal adaptin-like protein) autoimmunity appears rare, is accompanied by ataxia (sensory or cerebellar), and is potentially treatable.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Honorat JA, Lopez-Chiriboga AS, Kryzer TJ, et al. Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG. Neurology. 2019. PMID: 31371564. doi:10.1212/WNL.0000000000008061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。